Product Description

The Nociceptin/Orphanin FQ Peptide Receptor (NOP) is the fourth member of the opioid receptor family, a G protein-coupled receptor that binds its endogenous ligand, nociceptin/orphanin FQ, rather than classic opioid peptides. It is widely expressed throughout the central nervous system (e.g., cerebral cortex, amygdala, hippocampus, spinal cord) and some peripheral tissues. The NOP receptor has complex functions, modulating pain perception (its effects can be bidirectional, producing both analgesia and hyperalgesia), mood and stress responses, learning and memory, reward behaviors, as well as food intake and locomotor activity. Unlike classic mu receptor agonists, NOP agonists do not produce typical opioid-like respiratory depression or high addictive potential, making the NOP receptor a promising target for developing novel non-addictive analgesics and anxiolytic/antidepressant drugs.

ScreeningBio’s HEK293T/Human NOP β-Arrestin cell line is an ideal tool for studying GPCR/β-arrestin interactions. In this system, the GPCR C-terminus is fused to a smallBiT tag, and the β2-arrestin N-terminus is fused to a largeBiT tag. Upon receptor activation, GPCR/β-arrestin interaction brings the two fragments together to reconstitute an active NanoLuc enzyme, which can be quantified using the NanoBiT substrate. This cell line is designed to evaluate a compound’s ability to activate the β-arrestin signaling pathway.